Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Nasal Spray 16.5 g |
|
34624 | 19256 |
Dosage
Administer STERONASE AQ Nasal Spray by the intranasal route only. Shake STERONASE AQ Nasal Spray well before each use.
Adults and Adolescents 12 years of Age and older: The recommended starting and maximum dose is 220 micrograms as 2 sprays in each nostril once daily. Titrate an individual patient to the minimum effective dose to reduce the possibility of side effects. When the maximum benefit has been achieved and symptoms have been controlled, reducing the dose to 110 mcg per day (one spray in each nostril once a day) has been shown to be effective in maintaining control of the allergic rhinitis symptoms.
Children 6 to 12 years of age: The recommended starting dose is 110 micrograms per day given as 1 spray in each nostril. Children not responding adequately to 110 mcg per day may use 220 mcg (2 sprays in each nostril) once daily. Once symptoms are controlled, patients should be maintained on the lowest effective dose.
Children 2 to 5 years of age: The recommended and maximum dose is 110 mcg per day given as one spray in each nostril once daily.
STERONASE AQ Nasal Spray is not recommended for children under 2 years of age.
Indications
STERONASE AQ Nasal Spray is indicated for the treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 2 years of age and older.
Contra-Indications
Hypersensitivity to the active substance or to any of the excipients.
Special Precautions
See prescribing information for full details.
Side Effects
See prescribing information for full details.
Drug interactions
No interactions with other medicaments are known.
Pregnancy and Lactation
Clinical experience in pregnant women is limited. In animal studies, corticosteroids have been shown to induce teratogenic effects. Triamcinolone acetonide may pass into human breast milk.
Triamcinolone acetonide should not be administered during pregnancy or lactation unless the therapeutic benefit to the mother is considered to outweigh the potential risk to the foetus/baby.
Overdose
Like any other nasally administered corticosteroid, acute overdosing with STERONASE AQ Nasal Spray is unlikely in view of the total amount of active ingredient present. In the event that the entire contents of the bottle were administered all at once, via either oral or nasal application, clinically
significant systemic adverse events would most likely not result. The patient may experience some gastrointestinal upset if taken orally.
